Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 1363-1368

  Wang, Li ^a   Xie, Pei Gen ^b   Lin, Ying Li ^c   Ma, Jian Guo ^d   Li, Wen Ping ^d  

^a HEBEI UNIVERSITY OF ENGINEERING   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c XUZHOU CANCER HOSPITAL   (China)

^d HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Biological markers; DNA methylation; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTOCADHERIN 10; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CADHERIN; PCDH10 PROTEIN, HUMAN; PRIMER DNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DNA METHYLATION; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREOPERATIVE PERIOD; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; TUMOR INVASION; VERY ELDERLY; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; PROSTATIC NEOPLASMS;

CADHERINS; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA PRIMERS; HUMANS; MALE; POLYMERASE CHAIN REACTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905586787     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.891241     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z et al: Cancer statistics, 2014. Cancer J Clin, 2014; 64(1): 9-29
2. Mir MC, Joseph B, Zhao R et al: Effectiveness of epidural versus alternate analgesia for pain relief after radical prostatectomy and correlation with biochemical recurrence in men with prostate cancer. Res Rep Urol, 2013; 5: 139-45
3. Punnen S, Cooperberg MR, D'Amico AV et al: Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol, 2013; 64(6): 905-15
4. Qin GQ, He HC, Han ZD et al: Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer. Onco Targets Ther, 2014; 7: 137-46
5. Majumdar S, Buckles E, Estrada J et al: Aberrant DNA methylation and prostate cancer. Curr Genomics, 2011; 12(7): 486-505
6. Vasiljević N, Wu K, Brentnall AR et al: Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers, 2011; 30(4): 151-61
7. Goering W, Kloth M, Schulz WA: DNA methylation changes in prostate cancer. Methods Mol Biol, 2012; 863: 47-66
8. Narayan G, Xie D, Freddy AJ et al: PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosomes Cancer, 2013; 52(11): 1030-41
9. Danese E, Minicozzi AM et al: Epigenetic alteration: new insights moving from tissue to plasma-the example of PCDH10 promoter methylation in colorectal cancer. Br J Cancer, 2013; 109(3): 807-13
10. Ma JG, He ZK, Ma JH et al: Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer. J Int Med Res, 2013; 41(1): 38-47
11. Tang X, Yin X, Xiang T et al: Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Cancer Biomark, 2013; 12(1): 11-19
12. Lin YL, Li ZG, He ZK et al: Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer. J Int Med Res, 2012; 40(6): 2117-23
13. Lin YL, Li ZG, Guan TY: The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma. Urol Int, 2013; 90(2): 219-24
14. Li Z, Li W, Xie J et al: Epigenetic inactivation of PCDH10 in human prostate cancer cell lines. Cell Biol Int, 2011; 35(7): 671-76
15. Ito K: Prostate cancer in Asian men. Nat Rev Urol, 2014; 11(4): 197-212
16. Cottrell S, Jung K, Kristiansen G et al: Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol, 2007; 177(5): 1753-58
17. Shariat SF, Scherr DS, Gupta A et al: Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol, 2011; 64(8): 681-94
18. Bryniarski P, Paradysz A, Fryczkowski M: PSA mass as a marker of prostate cancer progression after radical prostatectomy. Med Sci Monit, 2011; 17(2): CR104-9
19. Chiam K, Ricciardelli C, Bianco-Miotto T: Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett, 2014; 342(2): 248-56
20. Haldrup C, Mundbjerg K, Vestergaard EM et al: DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol, 2013; 31(26): 3250-58
21. Mahapatra S, Klee EW, Young CY et al: Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res, 2012; 18(10): 2882-95
22. Chao C, Chi M, Preciado M et al: Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control, 2013; 24(9): 1615-41
23. Yu YP, Ding Y, Chen R et al: Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am J Pathol, 2013; 183(6): 1960-70
24. Hussain S, Haidar A, Bloom RE et al: Bicalutamide-induced hepatotoxicity: A rare adverse effect. Am J Case Rep, 2014; 15: 266-70
25. Ho A, Gabriel A, Bhatnagar A et al: Seasonality pattern of breast, colorectal, and prostate cancer is dependent on latitude. Med Sci Monit, 2014; 20: 818-24
26. Dietrich D, Meller S, Uhl B et al: Nucleic acid-based tissue biomarkers of urologic malignancies. Crit Rev Clin Lab Sci, 2014; 30: 1-27
27. Mearini L, Costantini E, Bellezza G et al: Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation? Urol Int, 2008; 81(1): 29-35
28. Briganti A, Suardi N, Gallina A et al: Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev, 2014; 40(1): 3-11
29. DeLancey JO, Wood DP Jr, He C et al: Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy. Urology, 2013; 81(2): 354-57
30. Schnoeller T, Jentzmik F, Rinnab L et al: Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol, 2013; 31(2): 253-59